IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

The KOL’s view suggests that Filspari’s market adoption may not be significantly affected by the recently approved competitor drug Vanrafia, despite Vanrafia’s less stringent monitoring ...

The KOL’s view suggests that Filspari’s market adoption may not be significantly affected by the recently approved competitor drug Vanrafia, despite Vanrafia’s less stringent monitoring requirements.

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy. Otsuka is hoping to file for approval of its ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...